Iruxol Mono

Collagenase Clostridium Histolyticum, the active ingredient in Iruxol Mono, is a proteolytic enzyme presented as a topical preparation for topical use. It facilitates enzymatic debridement of necrotic tissue in chronic and dermatologic wounds, helping to promote healthy tissue regeneration in patients with difficult‑to‑heal lesions.

GNH USA supplies Iruxol Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iruxol Mono is a proteolytic enzyme indicated for debridement in wound‑care and dermatology. It assists clinicians in removing non‑viable tissue to support healing.

- Chronic wounds: promotes removal of necrotic tissue to accelerate wound closure. - Pressure ulcers: enzymatically debrides dead tissue, facilitating recovery. - Diabetic foot ulcers: assists in clearing devitalized tissue, improving the wound environment.

Topical application of Iruxol Mono may be associated with local reactions.

Common Side Effects: - Redness at application site: mild irritation. - Swelling: localized edema. - Itching: transient pruritus. - Burning sensation: brief discomfort. - Dryness: mild skin desiccation. - Minor bleeding: slight oozing from debrided area.

Serious or Rare Side Effects: - Severe allergic reaction: hives, swelling of face or throat. - Extensive tissue damage: excessive enzymatic activity. - Infection: secondary bacterial colonisation. - Persistent ulceration: failure to heal. - Systemic hypersensitivity: fever, malaise. - Necrotizing fasciitis: rapidly spreading tissue necrosis.

When using Iruxol Mono, clinicians should observe several safety measures.

- Assess wound: confirm presence of necrotic tissue before application. - Avoid healthy tissue: limit exposure to viable skin to prevent unnecessary degradation. - Monitor for infection: watch for signs of bacterial overgrowth. - Contraindications: do not use on patients with known hypersensitivity to collagenase or protease enzymes. - Pediatric use: exercise caution, as safety data are limited. - Store below 25°C: keep in the original container, protect from moisture and light.

Iruxol Mono may interact with other topical agents or systemic medications.

Major Interactions (Avoid): - Concurrent use of other proteolytic enzymes: may increase tissue breakdown. - Topical corticosteroids: can reduce enzyme efficacy. - Anticoagulants applied locally: heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Systemic antibiotics: monitor for altered wound flora. - Immunosuppressants: may affect healing response. - Moisturizers containing occlusive agents: could impede enzyme activity.